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The government has cate­
gorically denied that there 
is any danger of antiretro­
viral (ARV) drug supp lies 
running short or drying 
up following a claim from one of their 
three supp liers, Aspen Pharma ceuti cals, 
that insuffi cient relief on the dismal rand 
exchange rate and single exit price (SEP) is 
creating a net loss.
The claim, originally floated by Aspen’s 
group CEO Stephen Saad when releasing his 
company’s financial results in March, was 
elaborated upon by his Senior Executive, 
Strategic Trade Development, Stavros 
Nicolaou, at a pioneering Medicines Summit 
held by Discovery Health on 15 May in 
Gauteng. Nicolaou said that the ARV fixed-
dose combinations (FDCs) were among the 
most expensive chronic medication drugs 
to produce and would be hit hardest by the 
ongoing dismal performance of the rand (25% 
depreciation), with the situation reaching 
crisis levels by the end of this year if the 
devaluation continues. He said the dilemma 
was affecting all chronic medications and 
claimed that one company, Fresenius Kabi, 
recently stopped supplying one drug line to 
South Africa (SA) because of it.
‘What I’m saying is that if the rand 
depreciated 25% on a trade-weighted basis and 
you’re only getting 5.8% (SEP adjustment), 
there’s obviously a shortfall which is not 
caught up – and it lands up compounding 
over a period of time, to the extent that 
manufacturers will say it’s no longer viable 
and withdraw from the market – that’s what 
happened with Fresenius Kabi,’ he added. 
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Government sources said the formula pro-
posed by the industry, including Aspen, 
would have produced an increase of 9%, so 
this would also have fallen short of the 25% 
deterioration in the rand.
‘Costing not a factor in 
our drug withdrawal’ – 
Fresenius Kabi
Wilna Stapelberg, MD of Fresenius Kabi, a 
critical care medications company based in 
Germany with a factory in Port Elizabeth, 
said costing had nothing to do with their 
artificial colloid Voluven (a plasma volume 
expander) being taken off the local market 
for six months from August last year. ‘While 
I agree with Stavros that pricing is a huge 
issue that’s becoming more and more diffi-
cult in SA, the issue with Voluven was a 
European Union (EU) one involving risks 
and bene fits, and the UK and SA’s Medicines 
Control Council followed suit.’ She said 
that after re assessment of the drug’s side-
effects, and ‘due to doctor demand’, it was 
reinstated in the market. The episode had 
‘nothing to do with the health department 
only giving us 5.8% on the SEP, or the 
exchange rate – I think Stavros got it a little 
bit wrong’. Stapelberg warned that it was 
easy for bulk buyers (read governments) 
to say that if one company didn’t provide, 
another would: ‘there are always lead times 
to manufacture and patients sit without 
products in that time’. She added that she’d 
‘never understand why government wants 
to control the private sector’.
Elaborating on the introduction of FDCs 
into the SA ARV supply chain and its effects 
on costs, Nicolaou said if government was 
ordering, for example, four million packs 
a month and patients were not converting 
from the single-component drug regimen, 
now being phased out, ‘you end up vastly 
overstocked on FDCs’. ‘If uptake on the 
ground and depot level is not consistent 
with production, then you tie up massive 
amounts of working capital,’ he told the 
Medicines Summit delegates. Making a 
point in the presence of the national drug 
committee chairperson, Professor Fatima 
Suleman, Head of the School of Pharmacy 
Practice at the University of KwaZulu-Natal, 
he said the ARV companies’ experience of 
the regulatory relief allowed by Regulation 9 
of the Medicines and Controlled Substances 
Act (the so-called ‘extraordinary increase’ 
provision) was that it was ‘so laden with 
red tape’ as to be wholly ineffective. ‘It’s 
fine when the rand is strong – but when 
there is sustained weakness and no price 
relief through the SEP method, we’ll see 
more and more distressed assets with them 
discontinued or sold off,’ he predicted. 
Fresenius Kabi had tried ‘for many years’ to 
secure a Regulation 9 ruling, but eventually 
gave up, he claimed. The industry’s 
experience was that the regulator ‘hardly 
ever’ allowed an application, and ‘you end 
up with forms just being sent back and forth’. 
Anban Pillay, Deputy Director-General 
of Health for Regulation and Compliance 
Management, countered that the procedure 
for a regulation 9 application was clearly 
defined and all the information available and 
based on an applicant proving exceptional 
circumstances with evidence. ‘If the evidence 
does not prove the case we cannot approve it. 
This is not called red tape but an evidence-
based process,’ he added.
National Health Minister Aaron Motsoaledi’s 
‘coup’ in securing a 53% drop in ARV drug 
prices – and the introduction of FDCs – 
were globally hailed as a moral, economic 
and adherence-enhancing victory. Pillay said 
the ARV tender contracts included a defined 
formula to adjust for exchange rate variation 
averaging the exchange rate  – which he 
conceded was ‘bad news for pharma’ if 
the rand progressively weakened. While 
expecting that companies would take that 
risk into consideration when pricing their 
products, government had not planned for 
such a dramatic weakening of the rand. 
‘There was nothing malicious in it, we agreed 
that they didn’t anticipate it and we didn’t 
plan for it to happen, so we settled in the end 
by funding half the difference, in spite of this 
not being in the contract. It would cost us 
millions to fund the entire difference in the 
exchange rate, which is what Aspen wants us 
to do,’ he said.
‘Aspen wanted twice 
the price adjustment 
of other suppliers’ – 
government
Mylan and Cipla had accepted the amen ded 
deal, but Aspen wanted a 100% adjustment. 
Aspen and Mylan each supply SA with about 
a million FDC packs per patient-month and 
Cipla about 500 000. Pillay said the original 
price from Aspen was about R96 per pack, 
with Cipla slightly lower and Mylan, slightly 
higher. ‘Those are the prices they came in 
with – the agreed currency adjustment moves 
the prices higher.’
Aspen needed to be ‘fully transparent’ about 
its costs and take full responsibility for having 
signed a contract that put them at major 
risk. ‘They’re sitting with lots of stock, but 
we also have Adcock who have lots of stock 
– Adcock will give it to us at a lower price
than Aspen are currently supplying.’ He said 
that Aspen raising the danger of stock-outs 
was ‘the most powerful weapon they have’. 
‘I’ve called Myland and Cipla and they don’t 
know what he’s talking about – they want 
to supply even more. If Aspen want to step 
down, Mylan will increase production and so 
will the others.’ Pillay flatly denied Nicolaou’s 
contention that government had asked Cipla 
to provide 700 000 FDC packs, but that 
Cipla had insisted on capping production at 
500 000. ‘They never agreed to supply more 
than 500 000, because that was their capacity 
– it had nothing to do with the exchange
rate,’ he said. Pillay admitted there was a 
problem with FDC patient uptake ‘at facility 
level’, with this currently standing at about 
60%. ‘Some patients believe three drugs (the 
former official ARV regimen) are stronger 
than the single FDC drug, and some doctors 
are reluctant to change to FDC because their 
patients are doing well on the three separate 
pills.’ This ‘lack of conversion’ resulted in a 
problem for all three drug suppliers, with 
orders from the nine provinces out of kilter 
Dr Anban Pillay, Deputy Director-General of 
Health for Regulation and Compliance Manage-
ment.
Pillay said the ARV tender 
contracts included a defined 
formula to adjust for exchange rate 
variation averaging the exchange 
rate – which he conceded was 
‘bad news for pharma’ if the rand 
progressively weakened.
IZINDABA
463       July 2014, Vol. 104, No. 7
with the FDC uptake they wanted. The 
national health department had wanted to 
convert all eligible patients (about 90% of 
adults) much sooner than had been the case.
Turning to the SEP, Pillay emphasised 
that this legislation only affected the private 
sector (about 10% of all patients on ARV 
therapy). With this system, government 
applied an industry-proposed formula of 
70% of the consumer price index (CPI), 
15% on the rand/dollar exchange rate 
and 15% on the rand/euro exchange rate. 
Manufacturers had argued that this was the 
basis of their cost structure. However, over 
time government had done its research and 
‘realised that this is not true’.
‘If you look at the originator medicines you 
see the research and development component 
built into the price. The question then 
becomes, does the R&D component fluctu-
ate with CPI or the rand/dollar exchange 
rate? The answer is no. So therefore giving 
the manufacturer that formula at the quoted 
price is not a fair adjustment. It has to be on 
what their true costs are’.
Latest meeting 
fails government 
transparency demands
Pillay revealed that his team met with the 
three drug companies as recently as 26 May 
and told them it was prepared to make a 
SEP formula adjustment – provided they 
were transparent on their true costs. ‘They 
said originator head offices would never 
reveal that,’ he said. Asked to summarise his 
position, Pillay responded: ‘My responsibility 
is to make sure public funds are appropriately 
spent. I believe the money spent on ARVs 
must be appropriately used so we can treat 
as many patients as possible.’
Responding to the suggestion that the 
exchange control situation might result in 
supplies being cut, he said: ‘We have a 
very good surveillance system in place and 
we’d detect any decreases in supply – we 
have other options available at affordable 
prices for South Africans.’ Pillay emphasised 
that SA now had the lowest ARV prices 
in the world and together with other big 
procurement agencies, the Global Fund (on 
behalf of developing countries) and Pepfar, 
purchased 90% of the globe’s supplies. ‘So 
we know exactly what suppliers are capable 
of and their constraints. If there are any 
risks, the signals would quickly come from 
our fellow buyers. We’re very sensitive to 
interrupted supplies. If there’s a drug plant 
fire or strike, we get to know about it very 
quickly and work out whether to shift orders 
somewhere else – or whatever the situation 
demands.’
‘We’ll never stop 
supplies in favour of 
profits’ – Cipla
Paul Miller, CEO of Cipla SA, confirmed 
that the depreciation of the rand had affec ted 
ARV margins and that the price of chronic 
medication was an issue. However, the key 
challenge in helping people living with HIV 
was continuity of supply ‘of these life-saving 
medicines, along with ensuring all those on 
single therapies are converted onto fixed-
dose combinations’. Cipla had a duty, both to 
government and to the SA public, to ensure 
that chronic medication reached the end-
consumer. At no stage would Cipla not supply 
the country with key medication because 
of profit motives. ‘We remain committed to 
honouring the tender obligation to government 
to supply ARVs, despite pricing pressures. In 
addition, if the industry can collectively work 
together with government in limiting the effect 
of profit margins on supply, then government 
will be able to deliver on its mandate to ensure 
that ARV (and other chronic medication) 
supply is not affected,’ he added.
Chris Bateman
chrisb@hmpg.co.za
S Afr Med J 2014;104(7):461-463.  
DOI:10.7196/SAMJ.8540
